AI English summary of an SEC filing — figures as filed
NRG Energy NRGThe company said Lawrence S. Coben, who had been interim president and chief executive officer since August 1, 2024, was appointed president and chief executive officer effective August 1, 2024. Dr. Coben will also continue as chair of the Board.
Key points
AI summaryThe company said Lawrence S. Coben, who had been interim president and chief executive officer since August 1, 2024, was appointed president and chief executive officer effective August 1, 2024. Dr. Coben will also continue as chair of the Board.
The company said the employment agreement sets Dr. Coben's annual base salary at $1,450,000 and his annual bonus target at 125% of base salary. He will receive a supplemental RPSU grant with a target grant-date value of $3,300,791 for fiscal 2024, and will be eligible for an equity grant in fiscal 2025 with a target grant-date value equal to 825% of his base salary.
The company said that if Dr. Coben is terminated without cause or resigns for good reason, he will receive a lump sum payment equal to 2 times his annual base salary. If the termination occurs within 24 months after a change in control, the payment will instead equal 3 times the sum of his annual base salary and target annual bonus. The company will also reimburse COBRA premiums for 18 months.
The company said that under its Cooperation Agreement with Elliott Management entered into in November 2023, Anne Schaumburg and Paul Hobby will resign from the Board effective September 30, 2024, and the Board will then have 11 members. Antonio Carrillo was appointed Lead Independent Director effective August 1, 2024.
Summary
AI-writtenAnalysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.
Lawrence S. Coben Named President and CEO
The company said Lawrence S. Coben, who had been interim president and chief executive officer since August 1, 2024, was appointed president and chief executive officer effective August 1, 2024. Dr. Coben will also continue as chair of the Board.
Source · Based on the filing body and exhibits
Base Salary, Target Bonus and Equity Compensation Under Employment Agreement
The company said the employment agreement sets Dr. Coben's annual base salary at $1,450,000 and his annual bonus target at 125% of base salary. He will receive a supplemental RPSU grant with a target grant-date value of $3,300,791 for fiscal 2024, and will be eligible for an equity grant in fiscal 2025 with a target grant-date value equal to 825% of his base salary.
Source · Based on the filing body and exhibits
Severance and Change-in-Control Terms
The company said that if Dr. Coben is terminated without cause or resigns for good reason, he will receive a lump sum payment equal to 2 times his annual base salary. If the termination occurs within 24 months after a change in control, the payment will instead equal 3 times the sum of his annual base salary and target annual bonus. The company will also reimburse COBRA premiums for 18 months.
Source · Based on the filing body and exhibits
Board Changes: 2 Directors Resign, New Lead Independent Director Named
The company said that under its Cooperation Agreement with Elliott Management entered into in November 2023, Anne Schaumburg and Paul Hobby will resign from the Board effective September 30, 2024, and the Board will then have 11 members. Antonio Carrillo was appointed Lead Independent Director effective August 1, 2024.
Source · Based on the filing body and exhibits
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…